Company profileNeuromodulation
Motif Neurotech
A miniature, wirelessly powered brain stimulator for treatment-resistant depression.
- Location
- Houston, United States
- Founded
- 2022
- Class
- NeuromodulationNot counted among core BCI companies.
- Website
- motifneuro.tech
- Sources last checked
- 6 Oct 2026
What they are building
Develops DOT, an implant about the size of a blueberry that is seated in the skull above the dura, touches no brain tissue and is powered wirelessly from outside the head.
- Interface category
- Electrocorticography · Cortical surface stimulation
- Signal
- ECoG: Local field potentials, including high-gamma activityCortical stim: Electrical pulses through surface contacts
- Invasiveness
- Minimally invasive
- Recording / stimulation
- Stimulation
- Device
- DOT microstimulator — Miniature stimulator seated in the skull above the dura, powered wirelessly
- Regulatory status
- Investigational; FDA investigational device exemption granted in April 2026
- Main use cases
- Restore
Where they are clinically
Feasibility
Small early studies that test safety and whether the device can do what it is meant to.
Access today
Clinical study
Accessible only by enrolling in a registered clinical study.
- Shown in people
- No human result is published. RESONATE, registered for 20 participants, is recruiting.
- Still an aim
- Stimulation therapy for treatment-resistant depression from an implant seated in the skull.
- What stands in the way
- Efficacy: a controlled demonstration that stimulation from above the dura relieves depression.
On record here: 1 registered study · 20 participants planned or enrolled · 0 peer-reviewed papers
This technology remains experimental and is not an established treatment. Access is limited to registered clinical studies.
- 28 Apr 2026US FDA — Investigational device exemption. Permits a clinical study of an investigational device. Not a marketing authorisation.
Why this company matters
Motif shows where therapeutic BCI may scale first: psychiatric indications with very large patient populations and a procedure simpler than a craniotomy. It is a stimulation-first device, a reminder that 'BCI' increasingly covers therapy as well as control. No efficacy result exists yet: RESONATE, with 20 participants planned, is its first clinical trial.
Key milestones
Sep 2026
RESONATE study registered and recruiting at two US sites; 20 participants planned.
28 Apr 2026
FDA grants an investigational device exemption for the first clinical trial of DOT, as announced by Rice University.
Clinical programmes
- RESONATE
Study of a miniature epidural stimulator for depression.
FeasibilityRecruiting
20 estimatedNCT07594483
Leadership
Jacob Robinson
Co-founder and CEO
As publicly stated by the organisation. Not a complete list.
IP and patents
- 3
- patent families identified and counted as BCI
- 2025
- earliest first filing among them
- 3
- first filed since 2021; the latest years are incomplete
- 0 of 3
- include a granted member, of those whose family record was read
Across the stack: families by layer
Themes, by number of families: electrodes and arrays (3), stimulation (3), closed loop (2), packaging and hermeticity (1), wireless power (1), wireless telemetry (1). A family can carry several.
Published in: United States (3), counted over the 3 families whose full record was read.
Representative families
- Systems and methods for improving externally powered cortical stimulation (xcs) waveformsfirst filed 2025 · Electrodes and arrays, Packaging and hermeticity, Wireless powerApplication
- Closed-loop externally powered electrical cortical stimulations (xcs)first filed 2025 · Electrodes and arrays, Stimulation, Closed loopApplication
- Systems and methods for dosing externally powered cortical stimulation (xcs) therapyfirst filed 2025 · Electrodes and arrays, Stimulation, Closed loopApplication
4 kept as adjacent neural technology
- Packaging and manufacture of magnetoelectric films for medical devices and devices produced therefromfirst filed 2024 · Packaging and hermeticity, Wireless power · adjacent, not counted as BCIApplication
- Enhancing power output of magnetoelectric films in miniature device enclosuresfirst filed 2024 · Packaging and hermeticity, Wireless power · adjacent, not counted as BCIApplication
- Treatment evaluation and recommendation using implantable magnetoelectric devicesfirst filed 2023 · Electrodes and arrays, Implant electronics, Wireless power · adjacent, not counted as BCIApplication
- Wireless monitoring and control of implantable magnetoelectric devicesfirst filed 2023 · Implant electronics, Wireless telemetry, Stimulation · adjacent, not counted as BCIGranted · US
Families found for Motif Neurotech in the EPO’s worldwide database, grouped so that one invention counts once. A filing shows what a company sought to protect. It does not show that the technology was built, is in a product, or works in people, and themes are read from titles, abstracts and classes, not from the claims. How to read this
Competitive context
Latest BCI Briefing coverage
Dossier Nº 02
What Does “Minimally Invasive” Actually Mean?
Sources
- 01
Company reportedRice University (press release, EurekAlert)28 Apr 2026Checked against source 6 Oct 2026
A release from the university the company came out of. The approval it reports is an investigational device exemption, which permits a study and is not a marketing authorisation.
- 02
ClinicalTrials.gov NCT07594483 (opens in a new tab)
Clinical registryClinicalTrials.gov29 Sep 2026Checked against source 3 Oct 2026
Registry record last updated 2026-09-29.